Curasight (One-pager): Funding of pipeline
The investment case for Curasight is driven by the successful development of its uPAR PET imaging platform uTRACE, and its targeted radionuclide therapy uTREAT, and entering partnerships to validate its technology, obtain funding, and potentially secure successful commercialization. In 2023, Curasight entered a partnership with France-based Curium regarding uTRACE in prostate cancer. The agreement provides up to USD 70 million in milestone payments and strengthens Curasight’s ability to source radioisotopes, which have previously been a bottleneck.
A lack of funding has delayed clinical progress year-to-date 2025. However, Curasight has initiated a rights issue to raise up to DKK 100 million to continue its clinical development. Its partner for uTRACE in prostate cancer, Curium, is supporting the issue, which is currently 47% covered by subscription and guarantee commitments. Improved financing may help de-risk the case and support a higher probability of success (PoS), compared to a biostatistical average of 15% for assets in phase II.
Disclaimer: HC Andersen Capital receives payment from Curasight for a Digital IR subscription agreement. /Claus Thestrup 07.05.2025 - 08:00 AM